After a surprise rejection at the beginning of 2026, the FDA has agreed to reconsider a T-cell therapy based on the same ...
A phase 2 study of botensilimab and AGEN1423, an anti-CD73-TGFβ-trap bifunctional antibody, with or without chemotherapy in subjects with advanced pancreatic cancer. This is an ASCO Meeting Abstract ...
Cost-effectiveness of dabrafenib plus trametinib in BRAFV600E-mutant pediatric low-grade glioma: A microsimulation study. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Recent data from a single-arm trial suggest favorable-risk patients with HPV-associated oropharyngeal carcinoma may benefit from a deintensified regimen.
Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...
The US Food and Drug Administration’s (FDA’s) approval decision about a new treatment for non–muscle invasive bladder cancer (NMIBC) hinges on whether a single-armed trial can be trusted to adequately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results